Open AccessEvaluation of CEDIA and DRI Drugs of Abuse Immunoassays for Urine Screening on a Thermo Indiko Plus Analyzer
Author(s) -
Köhler Katharina M.,
Hammer Raija,
Riedy Kathrin,
Auwärter Volker,
Neukamm Merja A.
Publication year - 2017
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22021
Subject(s) - methamphetamine , urine , amphetamine , drugs of abuse , mdma , ethyl glucuronide , abstinence , medicine , methadone , opiate , codeine , metabolite , substance abuse detection , pharmacology , drug , chemistry , psychiatry , alcohol , morphine , dopamine , alcohol consumption , biochemistry , receptor
Background For analysis of urine samples during abstinence control for driving ability assessment (medical and psychological assessment, MPA ), a reliable screening method for ethyl glucuronide and drugs of abuse (cannabinoids, opiates, cocaine, amphetamines, methadone, and benzodiazepines) is needed. Methods In this study CEDIA and DRI immunoassays were applied on a Thermo Fisher Scientific Indiko Plus analyzer. Precision and accuracy as well as sensitivity and specificity at the required cut‐offs for the MPA were evaluated. Results The specificity was satisfactory and ranged from 91% for methamphetamine to 100% for opiates, cocaine metabolite, amphetamine, EDDP , and benzodiazepines. Moreover, sensitivity was 100% for all assays except for cannabinoids (91%). Conclusion The presented method can therefore be recommended for abstinence control.